Myotonic dystrophy: approach to therapy
- PMID: 28376341
- PMCID: PMC5447481
- DOI: 10.1016/j.gde.2017.03.007
Myotonic dystrophy: approach to therapy
Abstract
Myotonic dystrophy (DM) is a dominantly-inherited genetic disorder affecting skeletal muscle, heart, brain, and other organs. DM type 1 is caused by expansion of a CTG triplet repeat in DMPK, whereas DM type 2 is caused by expansion of a CCTG tetramer repeat in CNBP. In both cases the DM mutations lead to expression of dominant-acting RNAs. Studies of RNA toxicity have now revealed novel mechanisms and new therapeutic targets. Preclinical data have suggested that RNA dominance is responsive to therapeutic intervention and that DM therapy can be approached at several different levels. Here we review recent efforts to alleviate RNA toxicity in DM.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Figures
Similar articles
-
Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.Curr Neurol Neurosci Rep. 2002 Sep;2(5):465-70. doi: 10.1007/s11910-002-0074-6. Curr Neurol Neurosci Rep. 2002. PMID: 12169228 Review.
-
Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms.Biochim Biophys Acta. 2015 Apr;1852(4):594-606. doi: 10.1016/j.bbadis.2014.05.019. Epub 2014 May 29. Biochim Biophys Acta. 2015. PMID: 24882752 Review.
-
Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.Nucleic Acid Ther. 2020 Apr;30(2):80-93. doi: 10.1089/nat.2019.0811. Epub 2019 Dec 23. Nucleic Acid Ther. 2020. PMID: 31873063 Free PMC article.
-
Sense and Antisense DMPK RNA Foci Accumulate in DM1 Tissues during Development.PLoS One. 2015 Sep 4;10(9):e0137620. doi: 10.1371/journal.pone.0137620. eCollection 2015. PLoS One. 2015. PMID: 26339785 Free PMC article.
-
Myotonic dystrophy: RNA pathogenesis comes into focus.Am J Hum Genet. 2004 May;74(5):793-804. doi: 10.1086/383590. Epub 2004 Apr 2. Am J Hum Genet. 2004. PMID: 15065017 Free PMC article. Review.
Cited by
-
µLAS: Sizing of expanded trinucleotide repeats with femtomolar sensitivity in less than 5 minutes.Sci Rep. 2019 Jan 10;9(1):23. doi: 10.1038/s41598-018-36632-5. Sci Rep. 2019. PMID: 30631115 Free PMC article.
-
AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.Nucleic Acids Res. 2020 Mar 18;48(5):2531-2543. doi: 10.1093/nar/gkaa007. Nucleic Acids Res. 2020. PMID: 31965181 Free PMC article.
-
RNA-binding proteins in neurodegeneration: mechanisms in aggregate.Genes Dev. 2017 Aug 1;31(15):1509-1528. doi: 10.1101/gad.304055.117. Genes Dev. 2017. PMID: 28912172 Free PMC article. Review.
-
A KIF1C-CNBP motor-adaptor complex for trafficking mRNAs to cell protrusions.Cell Rep. 2025 Mar 25;44(3):115346. doi: 10.1016/j.celrep.2025.115346. Epub 2025 Feb 20. Cell Rep. 2025. PMID: 39982819 Free PMC article.
-
Expanded DNA and RNA Trinucleotide Repeats in Myotonic Dystrophy Type 1 Select Their Own Multitarget, Sequence-Selective Inhibitors.Biochemistry. 2020 Sep 22;59(37):3463-3472. doi: 10.1021/acs.biochem.0c00472. Epub 2020 Sep 10. Biochemistry. 2020. PMID: 32856901 Free PMC article.
References
-
- Brook JD, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell. 1992;68:799–808. - PubMed
-
- Liquori CL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293:864–867. - PubMed
-
- Kanadia RN, et al. Developmental expression of mouse muscleblind genes Mbnl1, Mbnl2 and Mbnl3. Gene Expr Patterns. 2003;3:459–462. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous